Interferon beta is a naturally occurring protein involved in the body's immune response.<br />Originally developed to treat asthma and chronic obstructive pulmonary disorder, it's also been used to treat multiple sclerosis for years.<br />Now, preliminary findings of a Phase 1 clinical trial from the UK claims interferon beta can help patients hospitalized with the novel coronavirus COVID-19.<br />According to UPI, UK manufacturer Synairgen says interferon beta reduces the risk for serious illness and the need for ventilator support in such patients.<br />The company's version of the drug, called SNG001, is delivered directly to the lungs with a nebulizer.<br />The trial's results have not been published in a medical or scientific journal and have not undergone the peer-review process.
